Walker Chandiok &Co LLP

Walker Chandiok & Co LLP

Unit No. 02, Second Floor,
BPTP Capital City,
Plot No – 2B, Sector-94, Noida,
Gautam Buddha Nagar - 201301
Uttar Pradesh, India

T +91 120 485 5999
F +91 120 485 5902

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Jubilant Pharmova Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Pharmova Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jubilant Pharmova Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associate (refer Annexure 1 for the list of subsidiaries and associate included in the Statement) for the quarter ended 30 June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. The Statement also includes the Group's share of net loss after tax and total comprehensive loss of ₹ Nil for the quarter ended on 30 June 2026, in respect of an associate, based on their interim financial information, which have not been reviewed by their auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, this interim financial information is not material to the Group.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the financial information certified by the management of the associate

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Ashish Gupta
Partner
Membership No. 504662
UDIN: 26504662MEWBRW1205

Place: Noida
Date: 10 August 2026

Annexure 1

List of entities included in the Statement

A) Name of Subsidiaries

1	Jubilant Pharma Limited
2	Jubilant Draximage (USA) Inc.
3	Jubilant Draximage Inc.
4	Draximage (UK) Limited
5	Jubilant Pharma Holdings Inc.
6	Jubilant Clinsys Inc.
7	Jubilant Cadista Pharmaceuticals Inc.
8	Jubilant HollisterStier LLC
9	Jubilant Pharma NV
10	Jubilant Pharmaceuticals NV
11	PSI Supply NV
12	Jubilant Biosys Limited
13	Jubilant Discovery Services LLC
14	Jubilant Clinsys Limited
15	Jubilant First Trust Healthcare Limited
16	Jubilant Draximage Limited
17	Jubilant Innovation (USA) Inc.
18	Jubilant HollisterStier Inc.
19	Draxis Pharma LLC
20	Drug Discovery and Development Solutions Limited
21	Trialstat Solutions Inc.
22	Jubilant HollisterStier General Partnership
23	Jubilant Generics Limited
24	Jubilant Pharma Australia Pty Limited
25	Jubilant Draximage Radiopharmacies Inc.
26	Jubilant Pharma SA Pty Limited
27	Jubilant Therapeutics India Limited
28	Jubilant Therapeutics Inc.
29	Jubilant Business Services Limited
30	Jubilant Episcribe LLC
31	Jubilant Prodel LLC
32	Jubilant Epipad LLC
33	Jubilant Epicore LLC
34	Jubilant Employee Welfare Trust
35	Jubilant Pharma UK Limited
36	Jubilant Biosys Innovative Research Services Pte. Limited
37	Jubilant Pharma ME FZ-LLC
38	1359773 B.C. Unlimited Liability Company
39	Jubilant Biosys France SAS
40	Jubilant Pharmaceutical Inc. (w.e.f. 30 December 2025)

B) Name of Associates

1. SPV Laboratories Private Limited
2. O2 Renewable Energy XVI Private Limited (share of profit/loss not required to be considered)

Jubilant Pharmova Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24116UP1978PLC004624

Website: www.jubilantpharmova.com, Email: investors@jubl.com, Tel: +91-5924-267437

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30 June 2026

(₹ in million)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Revenue from operations**				
	a) Sales/Income from operations	**22,211**	**22,722**	**18,789**	**82,250**
	b) Other operating income	83	178	218	546
	Total revenue from operations	**22,294**	**22,900**	**19,007**	**82,796**
2	Other income	199	237	120	660
3	**Total income (1+2)**	**22,493**	**23,137**	**19,127**	**83,456**
4	**Expenses**				
	a) Cost of materials consumed	6,383	6,428	5,205	23,203
	b) Purchases of stock-in-trade	869	845	730	3,131
	c) Changes in inventories of finished goods, stock-in-trade and work-in progress	235	(140)	247	109
	d) Employee benefits expense	7,535	7,669	5,911	27,006
	e) Finance costs	542	565	490	2,118
	f) Depreciation, amortisation and impairment expense	1,273	1,168	981	4,404
	g) Other expenses	4,792	4,705	4,018	16,749
	Total expenses	**21,629**	**21,240**	**17,582**	**76,720**
5	**Profit before share of loss of an associate and exceptional items (3-4)**	**864**	**1,897**	**1,545**	**6,736**
6	Share of loss of an associate	-	-	(1)	(3)
7	**Profit before exceptional items and tax (5+6)**	**864**	**1,897**	**1,544**	**6,733**
8	Exceptional items	-	137	-	592
9	**Profit before tax (7-8)**	**864**	**1,760**	**1,544**	**6,141**
10	**Tax expense**				
	- Current tax	296	655	375	1,607
	- Deferred tax charge/(credit)	4	(88)	144	559
	Total tax expense	**300**	**567**	**519**	**2,166**
11	**Profit for the period (9-10)**	**564**	**1,193**	**1,025**	**3,975**
12	**Other comprehensive income/(loss)**				
	i) a) Items that will not be reclassified to profit or loss	1	77	(4)	64
	b) Income tax relating to items that will not be reclassified to profit or loss	-	(4)	1	1
	ii) a) Items that will be reclassified to profit or loss	(192)	2,746	414	5,393
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other comprehensive (loss)/income for the period	**(191)**	**2,819**	**411**	**5,458**
13	**Total comprehensive income for the period (11+12)**	**373**	**4,012**	**1,436**	**9,433**
	Profit/(loss) attributable to:				
	Owners of the Company	565	1,194	1,029	3,985
	Non-controlling interest	(1)	(1)	(4)	(10)
	Other comprehensive (loss)/income attributable to:				
	Owners of the Company	(191)	2,820	412	5,464
	Non-controlling interest	-	(1)	(1)	(6)
	Total comprehensive income/(loss) attributable to:				
	Owners of the Company	374	4,014	1,441	9,449
	Non-controlling interest	(1)	(2)	(5)	(16)
14	**Earnings per share of ₹ 1 each (not annualized for the quarters)**				
	Basic (₹)	3.57	7.55	6.49	25.15
	Diluted (₹)	3.56	7.52	6.47	25.08
15	Paid-up equity share capital (face value per share ₹ 1)	158	158	158	158
16	Reserves excluding revaluation reserves (other equity)				70,770
	See accompanying notes to the Consolidated Unaudited Financial Results				

Jubilant Pharmova Limited

Notes to the Consolidated Unaudited Financial Results

Note 1: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter ended 30 June 2026

(₹ in million)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Segment revenue**				
	a. Radiopharma	10,221	9,900	8,686	36,901
	b. Allergy Immunotherapy	2,144	2,176	1,914	7,957
	c. Contract Development and Manufacturing Organisation - Sterile Injectables	5,198	5,465	3,926	18,126
	d. Contract Research, Development and Manufacturing Organisation	3,258	3,348	3,114	12,649
	e. Generics	1,734	2,144	1,660	7,735
	f. Proprietary Novel Drugs	-	-	-	-
	Total	**22,555**	**23,033**	**19,300**	**83,368**
	Less : Inter segment revenue	403	281	421	1,157
	Total segment revenue	**22,152**	**22,752**	**18,879**	**82,211**
	Add: Unallocable corporate	142	148	128	585
	Total revenue from operations	**22,294**	**22,900**	**19,007**	**82,796**
2	**Segment results (profit(+)/loss(-) before tax, exceptional items and interest from each segment)**				
	a. Radiopharma	780	778	986	3,599
	b. Allergy Immunotherapy	635	898	613	2,717
	c. Contract Development and Manufacturing Organisation - Sterile Injectables	73	559	431	2,063
	d. Contract Research, Development and Manufacturing Organisation	356	360	270	1,238
	e. Generics	(101)	174	(4)	276
	f. Proprietary Novel Drugs	(76)	(74)	(62)	(194)
	Total segment results	**1,667**	**2,695**	**2,234**	**9,699**
	Less : i. Interest (Finance costs)	542	565	490	2,118
	ii. Exceptional items and unallocable expenditure (net of unallocable income)	261	370	200	1,440
	Profit before tax	**864**	**1,760**	**1,544**	**6,141**
3	**Segment assets**				
	a. Radiopharma	38,572	36,792	28,819	36,792
	b. Allergy Immunotherapy	6,241	6,310	5,630	6,310
	c. Contract Development and Manufacturing Organisation - Sterile Injectables	63,551	60,583	50,095	60,583
	d. Contract Research, Development and Manufacturing Organisation	17,669	17,727	17,238	17,727
	e. Generics	11,787	12,419	12,029	12,419
	f. Proprietary Novel Drugs	3,384	3,308	2,773	3,308
	g. Unallocable corporate assets	18,533	18,088	13,449	18,088
	Total segment assets	**159,737**	**155,227**	**130,033**	**155,227**
4	**Segment liabilities**				
	a. Radiopharma	12,587	12,394	9,199	12,394
	b. Allergy Immunotherapy	1,048	1,310	784	1,310
	c. Contract Development and Manufacturing Organisation - Sterile Injectables	27,662	27,852	22,987	27,852
	d. Contract Research, Development and Manufacturing Organisation	4,557	4,417	3,821	4,417
	e. Generics	2,415	2,594	2,588	2,594
	f. Proprietary Novel Drugs	139	98	120	98
	g. Unallocable corporate liabilities	39,997	35,606	26,673	35,606
	Total segment liabilities	**88,405**	**84,271**	**66,172**	**84,271**

Jubilant Pharmova Limited

Notes to the Consolidated Unaudited Financial Results

2. These consolidated unaudited financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. The figures for the preceding quarter ended 31 March 2026, as reported in these consolidated unaudited financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to date figures until the end of third quarter of that financial year. Also, the figures until the end of the third quarter had only been reviewed and not subjected to audit. Further, previous period figures have been regrouped / reclassified to conform to the current period's classification.

4. The above consolidated unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10 August 2026. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with BSE Limited and National Stock Exchange of India Limited. For more details on consolidated unaudited results, visit Investors section of our website at www.jubilantpharmova.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Pharmova Limited

PRIYAVRAT BHARTIA
Digitally signed by PRIYAVRAT BHARTIA
Date: 2026.08.10 18:47:18 +05'30'

Priyavrat Bhartia
Managing Director

Place : New Delhi
Date : 10 August 2026